Showing 71 Results
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
The Pharmacy Quality Alliance, with support from NPC, developed a framework that defines a patient’s medication access journey and characterizes barriers frequently encountered while seeking…
NPC President and CEO John M. O'Brien writes about how we can better incorporate the needs of caregivers into our health care system and provide them the support they deserve.
- Elements of Value
Mitigating racial health disparities is critical to advancing equitable access to health care, including medications and other therapies. NPC joined other experts at an AMCP Partnership Forum earlier…
NPC submitted comments on the Medicare Program’s CY 2022 Physician Fee Schedule proposed rule recommending opportunities to enhance understanding of patient-reported outcomes and address barriers to…
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
On a recent webcast, NPC Vice President of Health Services Research Kimberly Westrich discusses the importance of patient-centered care and the benefits and opportunities of incorporating patient…
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.
A new study in JMCP found that patient input is rarely sought for coverage policies – although plans had processes to engage physicians and medical societies when developing coverage policies, no…
A new study by NPC and the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center found that health insurance plans do not ask patients for input when developing specialty drug…
NPC President and CEO John O'Brien discusses how prescription medicines and the pharmacists who provided them helped people stay healthy at home during the pandemic.
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…
- Real-World Data
The key to elevating patient voices is using the right tools when developing a value-based payment model: patient-reported measures (PRMs), tools that capture patients’ voices related to their care…
NPC Board Chair and BMS SVP Michael Ryan reflects on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about what it takes to bring…
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
Health care policy experts gathered for a panel discussion, “If the NIH Funds the Research, Should There Be a 'Government Discount?” focused on key questions regarding government funding for research…
- Pandemic Response
In his commentary for Chain Drug Review, NPC Interim President and CEO Dr. Robert Dubois explores the steps we can take to improve our current health care system in the wake of the COVID-19 pandemic.
- Pandemic Response